Clinical trials: sponsored by Jiangsu HengRui Medicine Co., Ltd.
CRC (Colorectal Cancer)
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Efficacy and safety of retlirafusp alfa combined with bevacizumab and chemotherapy with or without short-course radiotherapy in conversion therapy for advanced colorectal cancer liver metastases: an exploratory study.
- Trial name
- NCT07728019
- Testing
- SCRT, Retlirafusp alfa Injection, Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neuromuscular Blockade
Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults
The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Rocuronium.
- Trial name
- NCT07746726
- Testing
- HRS-9190, Rocuronium
- Where
- 2 sites in China
- Volunteers
- 320 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastroscopic and Colonoscopic Sedation
A Non-interventional Study of Remazolam Methyl Benzene Sulfonic Acid for Injection in Real-world Clinical Practice
This is a non-interventional study of remazolam toluenesulfonate (rebenin ®) for injection in Chinese patients. A total of 2000 patients were enrolled in this study based on the preliminary safety assessment of rebenin ®, and all…
- Trial name
- NCT05254366
- Testing
- Remimazolam Tosilate for Injection
- Where
- 19 sites in China
- Volunteers
- 2,022 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
- Trial name
- NCT06568094
- Testing
- HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Resectable Esophageal Squamous Cell Carcinoma
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced…
- Trial name
- NCT05043688
- Testing
- Camrelizumab, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 426 people
- Sponsor
- Zhigang Li
Breast Cancer, HER2-low-expressing Breast Cancer
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial
This is a single-arm, prospective, non-randomized, single-center, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HR…
- Conditions
- Breast Cancer, HER2-low-expressing Breast Cancer, Hormone Receptor-positive Breast Cancer, Neoadjuvant Therapy
- Trial name
- NCT05165225
- Testing
- Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
B-cell Malignancy
Phase I Study of HRS-3005 in B-cell Malignancies
The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D).
- Trial name
- NCT07556822
- Testing
- HRS-3005
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
HER2-PositiveRecurrent or Metastatic Breast Cancer
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
- Trial name
- NCT06057610
- Testing
- SHR-A1811 Injection, SHR-A1811 Injection ； Pertuzumab Injection, Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
- Where
- China
- Volunteers
- 868 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Chinese Healthy Adult Subjects
Safety, Tolerability and Pharmacokinetic Studies of HRS-2183 for Injection in Healthy Chinese Subjects After Single and Multiple Administration
This study mainly evaluated the safety and tolerability, as well as the pharmacokinetic characteristics, of the injectable drug HRS-2183 after single and multiple administrations in healthy subjects.
- Trial name
- NCT07232758
- Testing
- HRS-2183
- Where
- China
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Neuromuscular Blockade
Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults
The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium.
- Trial name
- NCT07446309
- Testing
- HRS-9190; under Inhalational Anesthesia, HRS-9190; under Intravenous Anesthesia, Cisatracurium (under Inhalational Anesthesia).
- Where
- 2 sites in China
- Volunteers
- 67 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Acute Myeloid Leukemia
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
- Trial name
- NCT05772273
- Testing
- Azacitidine, Donor lymphocyte infusion, Camrelizumab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Advanced Colorectal Cancer Expressing HER2
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2
This global study is being conducted to evaluate the safety and determine the recommended phase 3 dose of trastuzumab rezetecan in combination with mFOLFOX6 chemotherapy (dose level -1) and bevacizumab as first-line treatment in…
- Trial name
- HORIZON-CRC221 (NCT07796763)
- Testing
- Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT05942001
- Testing
- HRS-5041, Docetaxel injection, Abiraterone acetate tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Abirritation in the ICU
A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)
The purpose of this study is to evaluate the efficacy and safety of Tegileridine Fumarate lnjection for prolonged abirritation(48h to 72h) during mechanical ventilation in the ICU.
- Trial name
- NCT07372924
- Testing
- Tegileridine Fumarate lnjection, Remifentanil Hydrochloride for Injection
- Where
- 2 sites in China
- Volunteers
- 121 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Psoriatic Arthritis
To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.
- Trial name
- NCT04957550
- Where
- China
- Volunteers
- 418 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The study is being conducted to evaluate the efficacy and safety of HRS-4508 in subjects with advanced or metastatic solid tumors and explore the reasonable dosage of HRS-4508.
- Trial name
- NCT06598735
- Testing
- HRS-4508
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery.
- Trial name
- NCT06507436
- Testing
- Herombopag tablets
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients
This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
- Trial name
- NCT06649773
- Testing
- Noiiglutide Injection
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants
This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the pharmacokinetics of HRS-6209 capsules (old and new formulation) in healthy participants.
- Trial name
- NCT07610148
- Testing
- HRS-6209 Capsule (old formulation), HRS-6209 Capsule (new formulation)
- Where
- China
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer
A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
This is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant trastuzumab.
- Trial name
- NCT03980054
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 2,135 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.